<!DOCTYPE html><html lang="en"><head><meta charset="UTF-8"><meta name="viewport" content="width=device-width,initial-scale=1.0"><title>Type 1 Diabetes — SugarWise</title><link rel="stylesheet" href="styles.css"><link rel="icon" type="image/svg+xml" href="favicon.svg"><link rel="manifest" href="manifest.json"><meta name="theme-color" content="#1a7a5a"><meta property="og:type" content="website"><meta property="og:site_name" content="SugarWise"><meta property="og:url" content="https://aravindcleaerr.github.io/diabetes-guide/type1-diabetes.html"><meta property="og:description" content="Free educational diabetes management guide. Not medical advice."></head><body>
<a href="#main" class="skip-link">Skip to content</a>
<nav class="navbar"><div class="navbar-inner"><a class="brand" href="index.html">SugarWise</a><a class="home-link" href="index.html">All Topics</a></div></nav>
<div class="container" id="main" role="main">
<div class="page-header"><h1>Type 1 Diabetes</h1><p>Autoimmune diabetes — causes, symptoms, diagnosis, and lifelong insulin management</p></div>
<div class="last-reviewed">Content last reviewed: January 2026 | AI-assisted content</div>

<div class="illus">
<svg width="300" height="120" viewBox="0 0 300 120" xmlns="http://www.w3.org/2000/svg">
<!-- Beta cell -->
<circle cx="150" cy="60" r="30" fill="#e6f5ef" stroke="#1a7a5a" stroke-width="2"/>
<text x="150" y="57" text-anchor="middle" font-size="9" fill="#145e45" font-weight="700">Beta</text>
<text x="150" y="68" text-anchor="middle" font-size="9" fill="#145e45" font-weight="700">Cell</text>
<!-- T-cells attacking -->
<circle cx="80" cy="35" r="12" fill="#fee2e2" stroke="#e53e3e" stroke-width="2">
  <animate attributeName="cx" values="80;120;80" dur="3s" repeatCount="indefinite"/>
  <animate attributeName="cy" values="35;50;35" dur="3s" repeatCount="indefinite"/>
</circle>
<text x="80" y="38" text-anchor="middle" font-size="7" fill="#e53e3e" font-weight="700">
  T<animate attributeName="x" values="80;120;80" dur="3s" repeatCount="indefinite"/>
</text>
<circle cx="220" cy="40" r="12" fill="#fee2e2" stroke="#e53e3e" stroke-width="2">
  <animate attributeName="cx" values="220;180;220" dur="2.8s" repeatCount="indefinite"/>
  <animate attributeName="cy" values="40;52;40" dur="2.8s" repeatCount="indefinite"/>
</circle>
<circle cx="90" cy="90" r="10" fill="#fef3c7" stroke="#e8913a" stroke-width="2">
  <animate attributeName="cx" values="90;125;90" dur="3.2s" repeatCount="indefinite"/>
  <animate attributeName="cy" values="90;75;90" dur="3.2s" repeatCount="indefinite"/>
</circle>
<circle cx="210" cy="88" r="10" fill="#fee2e2" stroke="#e53e3e" stroke-width="1.5">
  <animate attributeName="cx" values="210;175;210" dur="2.6s" repeatCount="indefinite"/>
  <animate attributeName="cy" values="88;72;88" dur="2.6s" repeatCount="indefinite"/>
</circle>
<!-- Labels -->
<text x="40" y="16" font-size="9" fill="#e53e3e" font-weight="600">Immune cells</text>
<text x="150" y="108" text-anchor="middle" font-size="9" fill="#64748b">Autoimmune attack on beta cells</text>
</svg>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F6E1;&#xFE0F;</span> What Is Type 1 Diabetes?</h2>
<p>Type 1 diabetes (T1D) is a chronic autoimmune condition in which the body's immune system mistakenly attacks and destroys the insulin-producing beta cells in the islets of Langerhans within the pancreas. This results in an absolute deficiency of insulin, requiring lifelong exogenous insulin replacement from the time of diagnosis.</p>
<p>Type 1 diabetes accounts for approximately <strong>5–10%</strong> of all diabetes cases worldwide. While it is most commonly diagnosed in children and adolescents (previously called "juvenile diabetes"), it can develop at any age — including in adults over 40.</p>

<div class="note">
<strong>Key Distinction:</strong> Unlike Type 2 diabetes, Type 1 is not caused by lifestyle factors. It is an autoimmune disease with a strong genetic component, influenced by environmental triggers.
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F52C;</span> Causes and Pathophysiology</h2>

<h3>Autoimmune Destruction of Beta Cells</h3>
<p>In T1D, immune cells — primarily autoreactive CD4+ and CD8+ T lymphocytes — infiltrate the pancreatic islets (a process called insulitis) and selectively destroy beta cells. This destruction is gradual and can begin months to years before symptoms appear. Clinical diabetes becomes apparent when approximately <strong>80–90%</strong> of beta-cell function is lost.</p>

<h3>Autoantibodies</h3>
<p>Several autoantibodies serve as biomarkers for the autoimmune process and can be detected in the blood before the onset of clinical disease:</p>
<ul>
<li><strong>GAD65 antibodies (GADA):</strong> Antibodies against glutamic acid decarboxylase — the most common autoantibody in adults.</li>
<li><strong>Islet cell antibodies (ICA):</strong> Directed against cytoplasmic components of islet cells.</li>
<li><strong>Insulin autoantibodies (IAA):</strong> More common in young children; typically the first autoantibody to appear.</li>
<li><strong>IA-2 antibodies (IA-2A):</strong> Directed against the protein tyrosine phosphatase IA-2.</li>
<li><strong>Zinc transporter 8 antibodies (ZnT8A):</strong> Present in up to 60–80% of newly diagnosed T1D patients.</li>
</ul>
<p>The presence of two or more autoantibodies confers a lifetime risk of clinical T1D of nearly 100%.</p>

<h3>Genetic Factors</h3>
<p>The strongest genetic association is with the HLA (human leukocyte antigen) region on chromosome 6, particularly the HLA-DR and HLA-DQ genes. Specific high-risk genotypes include HLA-DR3/DR4-DQ8. However, most individuals with high-risk HLA genotypes do not develop T1D, indicating that environmental triggers are also necessary.</p>

<h3>Environmental Triggers</h3>
<p>Proposed environmental factors that may trigger or accelerate the autoimmune process include:</p>
<ul>
<li>Viral infections (enteroviruses, particularly Coxsackievirus B)</li>
<li>Early exposure to cow's milk proteins (controversial and not definitively proven)</li>
<li>Vitamin D deficiency</li>
<li>Gut microbiome alterations</li>
<li>Toxins and chemical exposures</li>
</ul>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F4C8;</span> Stages of Type 1 Diabetes</h2>
<p>T1D is now understood to progress through defined stages, which is important for screening and early intervention:</p>

<div class="table-wrap">
<table>
<thead>
<tr><th>Stage</th><th>Autoantibodies</th><th>Blood Glucose</th><th>Symptoms</th></tr>
</thead>
<tbody>
<tr><td><strong>Stage 1</strong></td><td>2 or more autoantibodies present</td><td>Normal (normoglycemia)</td><td>None</td></tr>
<tr><td><strong>Stage 2</strong></td><td>2 or more autoantibodies present</td><td>Abnormal (dysglycemia)</td><td>None</td></tr>
<tr><td><strong>Stage 3</strong></td><td>Autoantibodies typically present</td><td>Meets diabetes diagnostic criteria</td><td>Symptomatic diabetes</td></tr>
</tbody>
</table>
</div>

<div class="tip">
<strong>Tip:</strong> The FDA-approved monoclonal antibody teplizumab (Tzield) can delay the onset of Stage 3 T1D by a median of approximately 2 years in individuals at Stage 2. Screening at-risk family members for autoantibodies is increasingly recommended.
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1FA7A;</span> Symptoms</h2>
<p>The onset of symptoms in T1D is often more acute and dramatic than in T2D. The classic symptoms — often called the "polys" — result from hyperglycemia and the body's inability to use glucose for energy:</p>
<ul>
<li><strong>Polyuria:</strong> Frequent urination — the kidneys excrete excess glucose in urine, pulling water along with it (osmotic diuresis).</li>
<li><strong>Polydipsia:</strong> Excessive thirst — caused by dehydration from polyuria.</li>
<li><strong>Polyphagia:</strong> Increased hunger — cells are starved of glucose despite high blood sugar levels.</li>
<li><strong>Unintentional weight loss:</strong> The body breaks down fat and muscle for energy because it cannot use glucose. This can be rapid and significant.</li>
<li><strong>Fatigue and weakness:</strong> Cells lack the energy they need to function normally.</li>
<li><strong>Blurred vision:</strong> High blood glucose causes fluid shifts in the lens of the eye.</li>
<li><strong>Fruity-smelling breath:</strong> A sign of ketone production (see DKA below).</li>
<li><strong>Nausea, vomiting, and abdominal pain:</strong> Often associated with ketoacidosis at presentation.</li>
</ul>

<div class="warning">
<strong>Warning — Diabetic Ketoacidosis (DKA):</strong> DKA is a life-threatening emergency that can be the first presentation of T1D, especially in children. Without insulin, the body breaks down fat for fuel, producing ketone bodies (acetoacetate, beta-hydroxybutyrate, acetone). Ketones accumulate in the blood, causing metabolic acidosis. Symptoms include nausea, vomiting, abdominal pain, rapid deep breathing (Kussmaul breathing), confusion, and loss of consciousness. DKA requires immediate emergency medical treatment with IV fluids, insulin, and electrolyte correction.
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F9EA;</span> Diagnosis</h2>
<p>Diagnosis of T1D is based on clinical presentation combined with laboratory tests:</p>
<ul>
<li><strong>Blood glucose:</strong> Fasting glucose &ge; 126 mg/dL, random glucose &ge; 200 mg/dL with symptoms, or HbA1c &ge; 6.5%.</li>
<li><strong>Autoantibody testing:</strong> Positive for one or more diabetes-related autoantibodies (GAD65, IA-2, IAA, ZnT8).</li>
<li><strong>C-peptide:</strong> Low or undetectable — indicates minimal or absent endogenous insulin production. C-peptide is a byproduct of insulin synthesis and is a reliable marker of beta-cell function.</li>
<li><strong>Ketone testing:</strong> Blood or urine ketones may be elevated at diagnosis.</li>
</ul>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F465;</span> Latent Autoimmune Diabetes in Adults (LADA)</h2>
<p>LADA is a form of autoimmune diabetes that occurs in adults — typically over age 30 — and progresses more slowly than classic T1D. It is sometimes called "Type 1.5 diabetes."</p>

<h3>Characteristics of LADA</h3>
<ul>
<li>Onset in adulthood (usually &gt; 30 years of age)</li>
<li>Positive for at least one diabetes-associated autoantibody (most commonly GADA)</li>
<li>Does not require insulin for at least the first 6 months after diagnosis (initial presentation may resemble T2D)</li>
<li>Progresses to insulin dependence over months to years as beta cells are gradually destroyed</li>
<li>Patients are often of normal or slightly overweight BMI (not typically obese)</li>
</ul>

<div class="note">
<strong>Clinical Significance:</strong> LADA is frequently misdiagnosed as Type 2 diabetes. If a patient diagnosed with T2D is lean, fails to respond adequately to oral medications, or has rapid deterioration in glycemic control, autoantibody testing and C-peptide measurement should be performed to rule out LADA.
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F489;</span> Management of Type 1 Diabetes</h2>

<h3>Insulin Therapy</h3>
<p>All individuals with T1D require lifelong insulin replacement. Modern insulin regimens aim to mimic the natural pattern of insulin secretion:</p>
<ul>
<li><strong>Basal insulin:</strong> Long-acting insulin (glargine, detemir, degludec) provides background insulin to control glucose between meals and overnight.</li>
<li><strong>Bolus insulin:</strong> Rapid-acting insulin (lispro, aspart, glulisine) is taken before meals to cover the glucose rise from food (carbohydrate counting is used to determine the dose).</li>
<li><strong>Insulin pumps:</strong> Continuous subcutaneous insulin infusion (CSII) devices deliver rapid-acting insulin continuously, with user-programmed boluses for meals. Modern pumps can be paired with CGMs to form hybrid closed-loop systems.</li>
</ul>

<h3>Blood Glucose Monitoring</h3>
<ul>
<li><strong>Self-monitoring of blood glucose (SMBG):</strong> Finger-prick testing with a glucometer — recommended at least 4–8 times daily in T1D.</li>
<li><strong>Continuous glucose monitors (CGM):</strong> Devices such as Dexcom G7 or FreeStyle Libre provide real-time glucose readings every 1–5 minutes. CGM use is strongly recommended for all people with T1D.</li>
</ul>

<h3>Glycemic Targets</h3>
<div class="table-wrap">
<table>
<thead>
<tr><th>Metric</th><th>General Target</th></tr>
</thead>
<tbody>
<tr><td>HbA1c</td><td>&lt; 7.0% (or individualized)</td></tr>
<tr><td>Fasting / pre-meal glucose</td><td>80–130 mg/dL (4.4–7.2 mmol/L)</td></tr>
<tr><td>Post-meal glucose (1–2 hours)</td><td>&lt; 180 mg/dL (&lt; 10.0 mmol/L)</td></tr>
<tr><td>Time in Range (CGM 70–180 mg/dL)</td><td>&gt; 70% of readings</td></tr>
<tr><td>Time below range (&lt; 70 mg/dL)</td><td>&lt; 4% of readings</td></tr>
</tbody>
</table>
</div>

<h3>Nutrition</h3>
<ul>
<li>Carbohydrate counting is essential for accurate bolus insulin dosing.</li>
<li>No specific foods are "forbidden" — the goal is to match insulin to carbohydrate intake.</li>
<li>Understanding glycemic index and glycemic load can help predict postprandial glucose responses.</li>
<li>Consistent meal timing can simplify insulin management but is not mandatory with flexible regimens.</li>
</ul>

<h3>Exercise</h3>
<ul>
<li>Regular physical activity is encouraged and improves cardiovascular health and insulin sensitivity.</li>
<li>Exercise can cause hypoglycemia (during or hours after activity) — adjustments to insulin and/or carbohydrate intake are often needed.</li>
<li>Aerobic exercise tends to lower blood glucose; intense anaerobic exercise may temporarily raise it.</li>
<li>A CGM or frequent SMBG is particularly valuable during and after exercise.</li>
</ul>

<h3>Hypoglycemia Management</h3>
<p>Hypoglycemia (blood glucose &lt; 70 mg/dL) is the most common acute complication of insulin therapy. Treatment follows the "Rule of 15":</p>
<ul>
<li>Consume 15 grams of fast-acting carbohydrate (glucose tablets, juice, regular soda).</li>
<li>Wait 15 minutes and recheck blood glucose.</li>
<li>Repeat if glucose remains below 70 mg/dL.</li>
<li>Once normalized, eat a snack or meal to prevent recurrence.</li>
</ul>

<div class="warning">
<strong>Severe Hypoglycemia:</strong> If the person is unconscious or unable to swallow, do NOT give food or drink by mouth. Administer glucagon (injectable or nasal) and call emergency services. All T1D patients and their caregivers should have glucagon readily available and know how to use it.
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F441;&#xFE0F;</span> Long-Term Complications and Screening</h2>
<p>Regular screening for complications is essential. Recommended assessments include:</p>
<ul>
<li><strong>Eye exam (dilated fundoscopy):</strong> Annually, starting 5 years after diagnosis (or from puberty).</li>
<li><strong>Kidney function (eGFR and urine albumin-to-creatinine ratio):</strong> Annually, starting 5 years after diagnosis.</li>
<li><strong>Foot exam:</strong> Annually — checking for neuropathy, pulses, skin integrity.</li>
<li><strong>Lipid panel and blood pressure:</strong> At least annually.</li>
<li><strong>Thyroid function:</strong> Autoimmune thyroid disease (Hashimoto's, Graves') is more common in T1D — screen at diagnosis and periodically.</li>
<li><strong>Celiac screening:</strong> Celiac disease is more prevalent in T1D — screen at diagnosis and if symptoms arise.</li>
</ul>
</div>

<div class="section">
<h2><span class="icon-sm">&#x1F9E0;</span> Psychological and Emotional Aspects</h2>
<p>Living with T1D imposes a significant daily management burden. Common psychosocial challenges include:</p>
<ul>
<li><strong>Diabetes distress:</strong> Feeling overwhelmed by the constant demands of diabetes management.</li>
<li><strong>Fear of hypoglycemia:</strong> Can lead to intentional hyperglycemia or avoidance of activities.</li>
<li><strong>Diabetes burnout:</strong> Disengagement from self-care routines.</li>
<li><strong>Depression and anxiety:</strong> 2–3 times more common in people with diabetes than in the general population.</li>
<li><strong>Disordered eating:</strong> Including insulin omission for weight control ("diabulimia").</li>
</ul>
<p>Mental health support, peer support groups, and regular psychosocial screening should be integrated into diabetes care.</p>

<h3>T1D Management Journey</h3>
<div class="timeline">
<div class="timeline-item"><div class="timeline-title">Diagnosis &amp; Education</div><div class="timeline-text">Learn insulin injection, carb counting, and glucose monitoring basics</div></div>
<div class="timeline-item"><div class="timeline-title">Stabilization Phase</div><div class="timeline-text">Find basal/bolus doses; possible honeymoon period with lower insulin needs</div></div>
<div class="timeline-item"><div class="timeline-title">Ongoing Optimization</div><div class="timeline-text">Regular HbA1c checks, CGM adoption, refine ICR and ISF ratios</div></div>
<div class="timeline-item"><div class="timeline-title">Technology Integration</div><div class="timeline-text">Consider insulin pump, hybrid closed-loop system, smart pens</div></div>
<div class="timeline-item"><div class="timeline-title">Long-Term Screening</div><div class="timeline-text">Annual eye, kidney, foot, thyroid, and celiac screening from year 5</div></div>
</div>
</div>

<div class="page-nav">
<a class="prev" href="understanding-diabetes.html">Understanding Diabetes</a>
<a class="next" href="type2-diabetes.html">Type 2 Diabetes</a>
</div>
</div>
<div class="disclaimer">This content is for educational purposes only and does not replace professional medical advice. The creators of SugarWise are not medical professionals. Do not start, stop, or change any medication without consulting your doctor. In case of emergency, call 112 (India) or your local emergency number. <a href="terms-of-use.html">Read full Terms of Use &amp; Medical Disclaimer</a></div>
<div class="privacy-notice">SugarWise does not use cookies, collect personal data, or track users.</div>
<div class="footer"><span class="ai-badge">AI-Assisted Content</span><br>SugarWise &bull; Comprehensive Diabetes Management Companion &bull; <a href="terms-of-use.html">Terms of Use</a> &bull; Last updated: January 2026</div>
<button class="theme-toggle" id="themeToggle" aria-label="Toggle dark mode" title="Toggle dark mode">&#9790;</button>
<button class="scroll-top" aria-label="Scroll to top" aria-label="Scroll to top" id="scrollTop" title="Back to top">&uarr;</button>
<script>
var sb=document.getElementById('scrollTop');window.addEventListener('scroll',function(){sb.classList.toggle('visible',window.scrollY>400)});sb.addEventListener('click',function(){window.scrollTo({top:0,behavior:'smooth'})});
document.querySelectorAll('.accordion-header').forEach(function(h){h.addEventListener('click',function(){this.parentElement.classList.toggle('open')})});
</script>
<script>
if('serviceWorker' in navigator){navigator.serviceWorker.register('sw.js');}
(function(){var t=document.getElementById('themeToggle');var saved=localStorage.getItem('theme');if(saved){document.documentElement.setAttribute('data-theme',saved);t.textContent=saved==='dark'?'\u2600':'\u263E';}t.addEventListener('click',function(){var d=document.documentElement.getAttribute('data-theme')==='dark'?'':'dark';document.documentElement.setAttribute('data-theme',d);localStorage.setItem('theme',d);t.textContent=d==='dark'?'\u2600':'\u263E';});})();
</script></body></html>